At the center of medical innovation, Medtech CDMOs are powering growth through strategic M&A, rising venture capital interest and next-gen technologies. With growing demand for AI-enabled devices and minimally invasive solutions, the sector is evolving rapidly, particularly in the U.S., where market momentum outpaces Europe’s more fragmented landscape. As regulatory complexity increases, CDMOs are becoming essential partners for first-time launches and scalable growth.
What You'll Learn:
- Market dynamics driven by M&A activity, including major deals like J&J’s acquisition of Shockwave and V-Wave
- Growth areas fueled by venture capital, AI and minimally invasive technologies
- The expanding role of CDMOs in regulatory support and commercialization
- U.S. market strength versus European structural hurdles and consolidation potential
- Capital market insights, from IPOs to private equity opportunities
Medtech CDMOs offer a compelling opportunity for investors, operators and innovators to accelerate advancement in the healthcare ecosystem.
Download the Report
ALVAREZ & MARSAL BOLSTERS ITS HEALTHCARE PRACTICE IN SOUTHEAST ASIA (ASEAN) REGION WITH THE APPOINTMENT OF SANATH KUMAR AS MANAGING DIRECTOR
September 1, 2025
Leading global professional services firm Alvarez & Marsal (A&M) has announced the appointment of Sanath Kumar as Managing Director within its Southeast Asia and Australia (SEAA) business unit. Based in Singapore, Mr. Sanath will play a strategic role in building out A&M’s Healthcare and Life Sciences practice across ASEAN markets.
Next-Generation Antibodies: A New Era in Immuno-Oncology
August 25, 2025
As the immune checkpoint inhibitor (ICI) market nears a patent cliff, the $50B immuno-oncology (IO) field is now seeking to surpass the limitations of earlier ICIs by enhancing survival outcomes, broadening coverage, and overcoming resistance mechanisms.
Strategic Patience in GenAI - A smarter path to AI leadership
August 11, 2025
As Generative AI accelerates across industries, life sciences firms must seek to adopt strategic patience, prioritizing long-term enterprise value over generating short-term media headlines.
The U.S. Pharma Premium: Who’s Really Paying the Price?
June 30, 2025
For decades, the United States has shouldered a disproportionate share of global pharmaceutical costs, accounting for 70% of global biopharma profits and over 80% of new drug launches. While this has helped drive significant medical innovation and supported the majority of global drug launches, it has also resulted in higher out-of-pocket costs for American patients.
